Stephens & Co. Reiterates Overweight on NeoGenomics, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Mason Carrico has reiterated an Overweight rating on NeoGenomics (NASDAQ:NEO) and maintained a $19 price target.
July 30, 2024 | 2:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stephens & Co. analyst Mason Carrico has reiterated an Overweight rating on NeoGenomics and maintained a $19 price target.
The reiteration of an Overweight rating and the maintenance of a $19 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100